Who are Phentolamine Mesylate (NV-101)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PHENTOLAMINE, Norepinephrine Bitartrate In 5% Dextrose, nebulized epinephrine and nebulized albuterol, Nasal Decongestant, Ibuprofen + Pseudoephedrine Hydrochloride, almotriptan or pseudoephedrine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/phentolamine-mesylate-nv-101.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Phentolamine Mesylate (NV-101) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phentolamine Mesylate (NV-101) (Phentolamine Mesylate (NV-101)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: alpha-adrenergic receptor antagonist. Area: Cardiovascular.

phase 3 alpha-adrenergic receptor antagonist alpha-adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Phentolamine Mesylate (NV-101) (Phentolamine Mesylate (NV-101)) — Novalar Pharmaceuticals, Inc.. Phentolamine mesylate is an alpha-adrenergic receptor antagonist that works by blocking the action of norepinephrine, a neurotransmitter that can cause blood vessels to constrict.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Phentolamine Mesylate (NV-101) TARGET	Phentolamine Mesylate (NV-101)	Novalar Pharmaceuticals, Inc.	phase 3	alpha-adrenergic receptor antagonist	alpha-adrenergic receptor
PHENTOLAMINE	PHENTOLAMINE		marketed		alpha-adrenergic receptors	1952-01-01
Norepinephrine Bitartrate In 5% Dextrose	NOREPINEPHRINE	Pfizer	marketed	Catecholamine	alpha-adrenergic receptors, beta-adrenergic receptors	1950-01-01
nebulized epinephrine and nebulized albuterol	nebulized epinephrine and nebulized albuterol	Rambam Health Care Campus	marketed	Adrenergic agonist combination	Alpha-adrenergic receptors, Beta-2 adrenergic receptors
Nasal Decongestant	Nasal Decongestant	Engelhard Arzneimittel GmbH & Co.KG	marketed	Sympathomimetic decongestant	Alpha-adrenergic receptors (likely alpha-1)
Ibuprofen + Pseudoephedrine Hydrochloride	Ibuprofen + Pseudoephedrine Hydrochloride	Dr. Reddy's Laboratories Limited	marketed	NSAID + decongestant combination	COX-1/COX-2 (ibuprofen); alpha-adrenergic receptors (pseudoephedrine)
almotriptan or pseudoephedrine	almotriptan or pseudoephedrine	Clinvest	marketed	Triptan + sympathomimetic decongestant combination	5-HT1B/1D receptors (almotriptan); alpha-adrenergic receptors (pseudoephedrine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (alpha-adrenergic receptor antagonist class)

Novalar Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Phentolamine Mesylate (NV-101) — Competitive Intelligence Brief. https://druglandscape.com/ci/phentolamine-mesylate-nv-101. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab